ASMB

About Assembly Biosciences, Inc (ASMB) Stock

Assembly Biosciences, Inc (ASMB) closed the 2026-09-16 session at $25.48, down 2.41% versus the previous close (-0.63). The stock opened at $26.11 and traded between $25.13 and $26.69 during that session. Session trading volume was 349K shares. The volume-weighted average price (VWAP) is $25.74.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Assembly Biosciences, Inc has a market capitalization of $531.6 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ASMB is listed on the XNAS exchange. The company employs approximately 73 people. Assembly Biosciences, Inc is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2010-12-17.

On this page you can find market ASMB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.